Eliem Therapeutics News

ELYMDelisted Stock  USD 3.04  0.04  1.30%   
About 61% of Eliem Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Eliem Therapeutics suggests that many traders are alarmed regarding Eliem Therapeutics' prospects. Eliem Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Eliem Therapeutics. Many technical investors use Eliem Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
over a year ago at www.macroaxis.com         
Acquisition by Dunn Judith of 10000 shares of Eliem Therapeutics subject to Rule 16b-3
Macroaxis News
over a year ago at investing.com         
Eliem Therapeutics earnings missed by 0.47, revenue was in line with estimates
Investing News at Macroaxis
over a year ago at finance.yahoo.com         
Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights
Yahoo News
over a year ago at news.google.com         
Chinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updates - Y...
Google News at Macroaxis
over a year ago at news.google.com         
Does Eliem Therapeutics Inc Have What it Takes to be in Your Portfolio Tuesday - InvestorsObserver
Google News at Macroaxis
over a year ago at thelincolnianonline.com         
Eliem Therapeutics, Inc. Short Interest Down .4 percent in April
news
over a year ago at finance.yahoo.com         
Were Hopeful That Eliem Therapeutics Will Use Its Cash Wisely
Yahoo News
over a year ago at news.google.com         
Can Eliem Therapeutics Inc Stock Rise to the Top of Healthcare Sector Wednesday - InvestorsObserver
Google News at Macroaxis
over a year ago at news.google.com         
Royalty Pharma offers 100M upfront for slice of Karunas much ... - FierceBiotech
Google News at Macroaxis
over a year ago at www.macroaxis.com         
Eliem Therapeutics exotic insider transaction detected
Macroaxis News
over a year ago at www.macroaxis.com         
Exercise or conversion by Valerie Morisset of 255219 shares of Eliem Therapeutics subject to Rule 16...
Macroaxis News
over a year ago at news.google.com         
HC Wainwright Co. Reiterates Neutral on Eliem Therapeutics ... - Benzinga
Google News at Macroaxis
over a year ago at investing.com         
Eliem Therapeutics earnings beat by 0.04, revenue was in line with estimates
Investing News at Macroaxis
over a year ago at globenewswire.com         
Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights
Macroaxis News: globenewswire.com
over a year ago at news.google.com         
FDA clears Bigfoots connected diabetes system for Android - FierceBiotech
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Eliem Therapeutics that are available to investors today. That information is available publicly through Eliem media outlets and privately through word of mouth or via Eliem internal channels. However, regardless of the origin, that massive amount of Eliem data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Eliem Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Eliem Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Eliem Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Eliem Therapeutics alpha.

Eliem Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit
09/11/2024
2
Disposition of tradable shares by Emily Pimblett of Eliem Therapeutics at 8.06 subject to Rule 16b-3
09/20/2024
3
500,000 Shares in Eliem Therapeutics, Inc. Acquired by Ally Bridge Group NY LLC - MarketBeat
09/24/2024
4
ELYM Stock Earnings Eliem Therapeutics Reported Results for Q4 2023 - MSN
11/20/2024
Check out Eliem Therapeutics Hype Analysis, Eliem Therapeutics Correlation and Eliem Therapeutics Performance.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Other Consideration for investing in Eliem Stock

If you are still planning to invest in Eliem Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eliem Therapeutics' history and understand the potential risks before investing.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Equity Valuation
Check real value of public entities based on technical and fundamental data
Technical Analysis
Check basic technical indicators and analysis based on most latest market data